Boxer Capital Management LLC Makes New $7.27 Million Investment in iTeos Therapeutics, Inc. (NASDAQ:ITOS)

Boxer Capital Management LLC acquired a new stake in iTeos Therapeutics, Inc. (NASDAQ:ITOS - Free Report) during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 946,915 shares of the company's stock, valued at approximately $7,272,000. Boxer Capital Management LLC owned approximately 2.59% of iTeos Therapeutics at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in the business. JPMorgan Chase & Co. raised its stake in iTeos Therapeutics by 342.7% during the 4th quarter. JPMorgan Chase & Co. now owns 2,068,796 shares of the company's stock valued at $15,888,000 after buying an additional 1,601,477 shares during the last quarter. Renaissance Technologies LLC grew its holdings in shares of iTeos Therapeutics by 56.1% in the fourth quarter. Renaissance Technologies LLC now owns 837,200 shares of the company's stock worth $6,430,000 after acquiring an additional 300,800 shares during the period. Eversept Partners LP purchased a new stake in iTeos Therapeutics during the fourth quarter valued at $1,691,000. Dimensional Fund Advisors LP lifted its stake in shares of iTeos Therapeutics by 15.7% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,210,080 shares of the company's stock worth $9,293,000 after purchasing an additional 163,880 shares during the period. Finally, Raymond James Financial Inc. purchased a new position in shares of iTeos Therapeutics during the 4th quarter worth $1,159,000. 97.16% of the stock is currently owned by hedge funds and other institutional investors.

iTeos Therapeutics Stock Performance

ITOS stock traded down $0.59 during trading on Monday, hitting $7.18. 211,470 shares of the company's stock traded hands, compared to its average volume of 486,152. iTeos Therapeutics, Inc. has a 52 week low of $4.80 and a 52 week high of $18.75. The stock has a market capitalization of $274.81 million, a price-to-earnings ratio of -2.28 and a beta of 1.39. The business has a fifty day simple moving average of $6.59 and a 200 day simple moving average of $7.52.

iTeos Therapeutics (NASDAQ:ITOS - Get Free Report) last issued its quarterly earnings data on Monday, April 28th. The company reported ($0.80) earnings per share for the quarter, topping the consensus estimate of ($0.94) by $0.14. Research analysts forecast that iTeos Therapeutics, Inc. will post -3.49 earnings per share for the current fiscal year.

Analysts Set New Price Targets

ITOS has been the topic of a number of analyst reports. Wedbush reaffirmed an "outperform" rating and set a $25.00 price objective on shares of iTeos Therapeutics in a research report on Wednesday, March 5th. HC Wainwright reissued a "buy" rating and issued a $46.00 price objective on shares of iTeos Therapeutics in a research note on Thursday, March 6th. JPMorgan Chase & Co. lowered their target price on shares of iTeos Therapeutics from $22.00 to $15.00 and set an "overweight" rating on the stock in a research note on Thursday, March 6th. Finally, Wells Fargo & Company cut their target price on iTeos Therapeutics from $17.00 to $16.00 and set an "overweight" rating for the company in a research report on Tuesday, April 29th.

About iTeos Therapeutics

iTeos Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.